202 related articles for article (PubMed ID: 28859580)
1. Simulated Effects of Policies to Reduce Diabetes Risk Among Adults With Schizophrenia Receiving Antipsychotics.
Mulcahy AW; Normand SL; Newcomer JW; Colaiaco B; Donohue JM; Lave JR; Keeler E; Sorbero MJ; Horvitz-Lennon M
Psychiatr Serv; 2017 Dec; 68(12):1280-1287. PubMed ID: 28859580
[TBL] [Abstract][Full Text] [Related]
2. Metabolic Testing for Adults in a State Medicaid Program Receiving Antipsychotics: Remaining Barriers to Achieving Population Health Prevention Goals.
Morrato EH; Campagna EJ; Brewer SE; Dickinson LM; Thomas DS; Miller BF; Dearing J; Druss BG; Lindrooth RC
JAMA Psychiatry; 2016 Jul; 73(7):721-30. PubMed ID: 27167755
[TBL] [Abstract][Full Text] [Related]
3. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs.
Morrato EH; Druss B; Hartung DM; Valuck RJ; Allen R; Campagna E; Newcomer JW
Arch Gen Psychiatry; 2010 Jan; 67(1):17-24. PubMed ID: 20048219
[TBL] [Abstract][Full Text] [Related]
4. Quality of monitoring for metabolic effects associated with second generation antipsychotics in patients with schizophrenia on public insurance.
Moeller KE; Rigler SK; Mayorga A; Nazir N; Shireman TI
Schizophr Res; 2011 Mar; 126(1-3):117-23. PubMed ID: 21168994
[TBL] [Abstract][Full Text] [Related]
5. Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study.
Rajkumar AP; Horsdal HT; Wimberley T; Cohen D; Mors O; Børglum AD; Gasse C
Am J Psychiatry; 2017 Jul; 174(7):686-694. PubMed ID: 28103712
[TBL] [Abstract][Full Text] [Related]
6. Continuity of medication management in Medicaid patients with chronic comorbid conditions: An examination by mental health status.
Farley JF; Hansen RA; Domino ME; Borse M; Mahendraratnam N; Ray N; Maciejewski ML
Gen Hosp Psychiatry; 2017; 45():25-31. PubMed ID: 28274335
[TBL] [Abstract][Full Text] [Related]
7. Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.
Pallava A; Chadda RK; Sood M; Lakshmy R
Nord J Psychiatry; 2012 Jun; 66(3):215-21. PubMed ID: 22017264
[TBL] [Abstract][Full Text] [Related]
8. [Schizophrenia, diabetes mellitus and antipsychotics].
Gury C
Encephale; 2004; 30(4):382-91. PubMed ID: 15538314
[TBL] [Abstract][Full Text] [Related]
9. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs.
Taylor D; Young C; Esop R; Paton C; Walwyn R
Br J Psychiatry; 2004 Aug; 185():152-6. PubMed ID: 15286067
[TBL] [Abstract][Full Text] [Related]
10. Second-Generation Antipsychotic Prescribing Patterns for Pediatric Patients Enrolled in West Virginia Medicaid.
Melvin KE; Hart JC; Sorvig RD
Psychiatr Serv; 2017 Oct; 68(10):1061-1067. PubMed ID: 28566023
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.
Lambert BL; Chou CH; Chang KY; Tafesse E; Carson W
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):417-25. PubMed ID: 15786516
[TBL] [Abstract][Full Text] [Related]
12. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
[TBL] [Abstract][Full Text] [Related]
13. New-onset treatment-dependent diabetes mellitus and hyperlipidemia associated with atypical antipsychotic use in older adults without schizophrenia or bipolar disorder.
Erickson SC; Le L; Zakharyan A; Stockl KM; Harada AS; Borson S; Ramsey SD; Curtis B
J Am Geriatr Soc; 2012 Mar; 60(3):474-9. PubMed ID: 22288652
[TBL] [Abstract][Full Text] [Related]
14. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
[TBL] [Abstract][Full Text] [Related]
15. Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study.
Østbye T; Curtis LH; Masselink LE; Hutchison S; Wright A; Dans PE; Schulman KA; Krishnan RR
Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):407-15. PubMed ID: 15372671
[TBL] [Abstract][Full Text] [Related]
16. Spillover effects of state medicaid antipsychotic prior authorization policies in US commercially insured youth.
Spence O; Reeves G; dosReis S
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1064-1071. PubMed ID: 32558177
[TBL] [Abstract][Full Text] [Related]
17. Use of administrative data to identify off-label use of second-generation antipsychotics in a Medicaid population.
Hartung DM; Middleton L; McFarland BH; Haxby DG; McDonagh MS; McConnell KJ
Psychiatr Serv; 2013 Dec; 64(12):1236-42. PubMed ID: 23999754
[TBL] [Abstract][Full Text] [Related]
18. Factors in second-generation antipsychotic switching patterns in a national sample of older veterans with schizophrenia.
Dassori AM; Copeland LA; Zeber JE; Miller AL
Psychiatr Serv; 2011 Jan; 62(1):47-53. PubMed ID: 21209299
[TBL] [Abstract][Full Text] [Related]
19. Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs.
Hansen RA; Maciejewski M; Yu-Isenberg K; Farley JF
Psychiatr Serv; 2012 Sep; 63(9):920-8. PubMed ID: 22706887
[TBL] [Abstract][Full Text] [Related]
20. Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics.
Bell RC; Farmer S; Ries R; Srebnik D
Psychiatr Serv; 2009 Dec; 60(12):1686-9. PubMed ID: 19952163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
